Akums Reports Q4 FY26 and Full Year FY26 Results with Healthy Top Line and Strong EBITDA Growth; Board Recommends Dividend
Published on: May 15, 2026, 3:45 p.m. | Source: The Tribune
New Delhi [India], May 15: Akums Drugs & Pharmaceuticals Ltd., India's largest Contract Development and Manufacturing Organisation (CDMO), announced its financial results for the fourth quarter and the full year ended March 31, 2026. The company delivered a steady performance during Q4 FY26, with healthy revenue growth and improved operating profitability driven by its core domestic CDMO business.
